Get started

Financials · MXCT

MaxCyte Inc. (MXCT) financials

For the twelve months ended Jun 30, 2026, MaxCyte Inc. reported $31.05M of revenue and -$35.64M of net income.

Revenue, TTM
$31.05M
Revenue growth, YoY
-13.2%
Net income, TTM
-$35.64M
Net margin
-114.8%
Free cash flow, TTM
-$23.64M
EPS, diluted, TTM
-$0.32
Cash
$15.04M
P/S
4.19
Market cap
$130.0M
Annual revenue$33.03M
FY2019FY2025
Annual net income-$44.63M
FY2019FY2025
Annual free cash flow-$36.18M
FY2019FY2025

MXCT revenue and earnings growth

MXCT revenueQ2 2026$7.27M

Quarter YoY
-14.5%
QoQ
-24.7%
FY YoY
-14.5%
5Y CAGR
+4.8%

MXCT revenue was $7.27M in fiscal Q2 2026 (ended Jun 30, 2026), down 14.5% from a year earlier and down 24.7% from the prior quarter. For the full fiscal 2025 it was $33.03M, down 14.5% from fiscal 2024. Compound annual growth was +4.8% over 5 years. It rose in 3 of the last 6 fiscal years.

MXCT net incomeQ2 2026-$8.87M

MXCT net income was -$8.87M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$12.36M a year earlier. For the full fiscal 2025 it was -$44.63M, compared with -$41.05M in fiscal 2024.

MXCT EPSQ2 2026-$0.08

MXCT diluted EPS was -$0.08 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.12 a year earlier. For the full fiscal 2025 it was -$0.42, compared with -$0.39 in fiscal 2024.

MXCT free cash flowQ2 2026-$4.72M

MXCT free cash flow was -$4.72M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$10.44M a year earlier. For the full fiscal 2025 it was -$36.18M, compared with -$29.26M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$33.03M$38.63M$41.29M$44.26M$33.89M$26.17M$21.62M
Cost of revenue$6.22M$7.10M$4.74M$5.10M$3.65M$2.77M$2.50M
Gross profit$26.80M$31.53M$36.55M$39.16M$30.25M$23.40M$19.12M
Research and development$20.82M$22.23M$23.82M$19.51M$15.41M$17.73M$17.59M
Selling, general and admin$28.12M$29.69M$30.07M$25.83M$18.68M$7.37M$5.56M
Operating income-$51.90M-$51.20M-$48.30M-$27.36M-$18.19M-$11.06M-$12.42M
Interest expense----$5.4K$21.7K$51.9K
Pre-tax income-$44.63M-$41.05M-$37.92M----
Income tax----$0$0$0
Net income-$44.63M-$41.05M-$37.92M-$23.57M-$19.08M-$11.82M-$12.89M
EPS, basic-$0.42-$0.39-$0.37-$0.23-$0.21-$0.17-$0.23
EPS, diluted-$0.42-$0.39-$0.37-$0.23-$0.21-$0.17-$0.23
Diluted shares106.4M104.8M103.3M101.7M90.6M69.5M56.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$20.07M$27.88M$46.51M$11.06M$47.78M$18.76M$15.21M
Short-term investments$82.98M$126.60M$121.78M$216.28M$207.26M$16.01M-
Receivables$3.50M$4.68M$5.78M$11.18M$6.88M$5.17M-
Inventory$7.55M$8.91M$12.23M$8.58M$5.20M$4.32M-
Current assets$118.37M$171.68M$190.19M$252.27M$270.43M$45.25M-
Total assets$202.51M$239.47M$268.27M$286.65M$284.12M$51.78M-
Current liabilities$14.27M$15.78M$17.86M$15.43M$15.62M$11.61M-
Total liabilities$31.02M$33.22M$36.11M$32.69M$21.22M$18.55M-
Shareholders' equity$171.49M$206.25M$232.17M$253.97M$262.90M$33.23M$13.60M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$34.41M-$27.61M-$21.69M-$14.78M-$10.68M-$8.78M-$8.80M
Capital expenditures$1.77M$1.65M$3.70M$18.48M$3.83M$2.07M$1.27M
Free cash flow-$36.18M-$29.26M-$25.39M-$33.26M-$14.51M-$10.85M-$10.07M
Investing cash flow$25.93M$6.93M$54.98M-$24.82M-$195.01M-$16.58M$454.5K
Financing cash flow$656.0K$2.06M$2.14M$2.89M$234.72M$28.90M$12.31M
Stock-based compensation$9.21M$13.08M$13.98M$11.75M$7.96M$2.47M$1.75M
Depreciation and amortization$4.34M$4.32M$4.17M$2.70M$1.42M$1.05M$613.5K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY-14.5%-6.4%-6.7%30.6%29.5%21.0%-
Gross margin81.2%81.6%88.5%88.5%89.2%89.4%88.4%
Operating margin-157.1%-132.5%-117.0%-61.8%-53.7%-42.3%-57.4%
Net margin-135.1%-106.3%-91.8%-53.3%-56.3%-45.2%-59.6%
Free cash flow margin-109.5%-75.8%-61.5%-75.1%-42.8%-41.5%-46.6%
Return on equity-26.0%-19.9%-16.3%-9.3%-7.3%-35.6%-94.8%
Return on assets-22.0%-17.1%-14.1%-8.2%-6.7%-22.8%-
Current ratio8.3010.8810.6516.3517.323.90-

Source: XBRL data MaxCyte Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MXCT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MXCT$31.05M-13.2%-$35.64M-114.8%$130.0M
IQV$17.31B+8.8%$1.40B8.1%$44.80B
INCY$6.01B+24.9%$403.41M6.7%$24.39B
MEDP$2.84B+20.4%$517.83M18.2%$18.27B
CRL$3.98B-1.2%$40.19M1.0%$16.17B
ICLR$8.25B+0.8%$229.34M2.8%$15.68B
ABSI$1.56M-62.3%-$121.08M-7756.4%$1.75B
OABI$40.21M+90.6%-$43.47M-108.1%$732.9M
NRC$143.79M+3.4%$6.13M4.3%$548.7M

MXCT FAQ

9 questions
  • What is MXCT revenue?
    MaxCyte Inc. (MXCT) reported $31.05M of revenue for the twelve months ended Jun 30, 2026. That is down 13.2% from the year before. Revenue for fiscal 2025 was $33.03M.
  • Is MXCT profitable?
    No. MaxCyte Inc. reported a net loss of $35.64M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does MXCT have?
    MaxCyte Inc. reported $15.04M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is MXCT revenue growing?
    MaxCyte Inc.'s revenue changed -14.5% in fiscal 2025, to $33.03M. Its compound annual growth rate was +4.8% over 5 years.
  • What is MXCT gross margin?
    MaxCyte Inc.'s gross profit was $24.60M on $31.05M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 79.2%.
  • What is MXCT free cash flow?
    MaxCyte Inc. generated -$23.64M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$22.98M less capital expenditures.
  • What is MXCT earnings per share?
    Diluted earnings per share were -$0.32 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did MXCT last report financial results?
    The latest statements here come from MaxCyte Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this MXCT financial data come from?
    Quantisnow builds these statements from the structured XBRL data MaxCyte Inc. files with the SEC. It is provided for information only and is not investment advice.